News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
223,872 Results
Type
Article (5005)
Company Profile (18)
Press Release (218849)
Section
Business (82203)
Career Advice (461)
Deals (15043)
Drug Delivery (8)
Drug Development (19075)
Employer Resources (30)
FDA (3675)
Job Trends (3908)
News (120117)
Policy (7501)
Tag
Academia (291)
Alliances (14752)
Alzheimer's disease (235)
Approvals (3684)
Artificial intelligence (34)
Bankruptcy (96)
Best Places to Work (2871)
Breast cancer (42)
Cancer (381)
Career advice (391)
CAR-T (27)
Cell therapy (94)
Clinical research (15934)
Collaboration (140)
Compensation (127)
COVID-19 (299)
C-suite (77)
Data (428)
Diabetes (33)
Diagnostics (2027)
Earnings (40401)
Employer resources (31)
Events (37511)
Executive appointments (258)
FDA (3876)
Funding (153)
Gene therapy (39)
GLP-1 (102)
Government (406)
Healthcare (5034)
Infectious disease (313)
Interviews (53)
IPO (7810)
Job creations (1120)
Job search strategy (360)
Layoffs (99)
Legal (2328)
Lung cancer (42)
Manufacturing (42)
Medical device (3847)
Medtech (3848)
Mergers & acquisitions (7398)
Metabolic disorders (103)
Neuroscience (310)
NextGen: Class of 2025 (1674)
Non-profit (728)
Northern California (787)
Obesity (48)
Opinion (30)
People (24445)
Phase I (4759)
Phase II (6924)
Phase III (5500)
Pipeline (391)
Postmarket research (625)
Preclinical (1850)
Press Release (66)
Radiopharmaceuticals (105)
Rare diseases (60)
Real estate (1872)
Regulatory (5071)
Research institute (299)
Resumes & cover letters (68)
Southern California (577)
Startups (1008)
United States (6018)
Vaccines (31)
Date
Today (73)
Last 7 days (284)
Last 30 days (905)
Last 365 days (10563)
2025 (1654)
2024 (11037)
2023 (13205)
2022 (18666)
2021 (19687)
2020 (18238)
2019 (13206)
2018 (10205)
2017 (10001)
2016 (9156)
2015 (12118)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (183)
Arizona (52)
Asia (11388)
Australia (1592)
California (1625)
Canada (618)
China (51)
Colorado (70)
Connecticut (83)
Europe (24310)
Florida (218)
Georgia (28)
Illinois (103)
Indiana (54)
Japan (57)
Maine (38)
Maryland (196)
Massachusetts (1331)
Michigan (81)
Minnesota (125)
New Jersey (483)
New York (410)
North Carolina (291)
Northern California (787)
Ohio (48)
Pennsylvania (296)
South America (274)
Southern California (577)
Tennessee (31)
Texas (188)
Utah (54)
Virginia (33)
Washington State (143)
223,872 Results for "pepgen corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne Muscular Dystrophy
Déjà Vu for PepGen as FDA Places Hold on DMD Drug
The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The company faced the same hurdle for an earlier neuromuscular candidiate in 2023.
December 16, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
February 24, 2025
·
11 min read
Press Releases
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 7, 2024
·
10 min read
Business
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2024.
May 14, 2024
·
10 min read
Press Releases
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1
February 24, 2025
·
10 min read
Press Releases
PepGen to Participate in Upcoming Investor Conferences
November 4, 2024
·
1 min read
Business
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PepGen Inc. (Nasdaq: PEPG) today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate developments.
March 6, 2024
·
11 min read
Business
PepGen Announces Executive Team Promotions - June 11, 2024
PepGen Inc. announced two executive team promotions effective immediately: Michelle Mellion, M.D., to Chief Medical Officer and Hayley Parker, Ph.D., to Senior Vice President, Global Regulatory Affairs.
June 11, 2024
·
3 min read
Genetown
PepGen to Participate in Upcoming Investor Conferences - March 13, 2024
PepGen Inc. announced that management will participate in the following upcoming investor conferences.
March 13, 2024
·
1 min read
Press Releases
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
October 8, 2024
·
7 min read
1 of 22,388
Next
